Arix Bioscience PLC
LSE:ARIX
Intrinsic Value
Arix Bioscience Plc is a global venture capital company. [ Read More ]
The intrinsic value of one
ARIX
stock under the Base Case scenario is
0.42
GBX.
Compared to the current market price of 142 GBX,
Arix Bioscience PLC
is
Overvalued by 100%.
Arix Bioscience PLC's market capitalization is 183.8m GBX.
ARIX stock price is 142 GBX.
ARIX stock (0.42 GBX) is 100% less than its price (142 GBX).
ARIX. Open DCF Valuation
ARIX stock (0.42 GBX) is 100% less than its price (142 GBX). Open Relative Valuation
ARIX has downside potential of 19% compared to the average analyst price target.
Open Wall St Estimates
ARIX's ROE (Return on Equity) for the past 12 months is positive and is equal to 6%.
ARIX's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -5%.
ARIX's Revenue has dropped by 65% over the past 12 months.
ARIX has negative Operating Income for the last twelve months.
ARIX has positive Net Income for the last twelve months.
ARIX has negative three-year average ROIC (Return on Invested Capital): -4%. The company is not efficient at using invested capital to generate operating income.
ARIX has negative three-year average ROE (Return on Equity): -6%. The company is not efficient at transforming stockholders' equity into net income.
ARIX has negative Free Cash Flow for the last twelve months.
ARIX's short-term assets (103m GBP) exceed its short-term liabilties (1m GBP).
ARIX's long-term assets (241m GBP) exceed its long-term liabilties (1m GBP).
ARIX's D/E (Debt to Equity) is very low and is equal to 0.
ARIX's Altman Z-Score is very high and is equal to 55.42.
Fundamental Analysis
Arix Bioscience PLC
Balance Sheet Decomposition
Arix Bioscience PLC
| Current Assets | 103.4m |
| Cash & Short-Term Investments | 101m |
| Receivables | 2.4m |
| Non-Current Assets | 137.2m |
| Long-Term Investments | 137.1m |
| PP&E | 90k |
| Current Liabilities | 1.4m |
| Accounts Payable | 1.4m |
| Other Current Liabilities | 37k |
Earnings Waterfall
Arix Bioscience PLC
|
Revenue
|
77k
GBP
|
|
Operating Expenses
|
-6.1m
GBP
|
|
Operating Income
|
-6m
GBP
|
|
Other Expenses
|
21m
GBP
|
|
Net Income
|
15m
GBP
|
Free Cash Flow Analysis
Arix Bioscience PLC
ARIX Profitability Score
Profitability Due Diligence
Arix Bioscience PLC's profitability score is 29/100. The higher the profitability score, the more profitable the company is.
Score
Arix Bioscience PLC's profitability score is 29/100. The higher the profitability score, the more profitable the company is.
ARIX Solvency Score
Solvency Due Diligence
Arix Bioscience PLC's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Score
Arix Bioscience PLC's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ARIX Price Targets Summary
Arix Bioscience PLC
According to Wall Street analysts, the average 1-year price target for
ARIX
is 115 GBX
.
Shareholder Return
ARIX Price
Arix Bioscience PLC
| Average Annual Return | 4.65% |
| Standard Deviation of Annual Returns | 68.62% |
| Max Drawdown | -63% |
| Market Capitalization | 183.8m GBX |
| Shares Outstanding | 129 390 000 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Arix Bioscience PLC
Country
Industry
Market Cap
Dividend Yield
Description
Arix Bioscience Plc is a global venture capital company. The firm is a holding company that is focused on generating value from the development and commercialization of technologies and discoveries. The firm's principal activity is to source, finance and develop healthcare and life science businesses across the world. The firm focuses on acquiring interests in, and provide operational oversight to, healthcare and life science businesses with which it partners in the healthcare and life science sector. The Company’s portfolio includes Harpoon Therapeutics, Inc. (HARP), Artios Pharma Ltd (Artios), Aura Biosciences Inc (Aura), LogicBio Therapeutics, Inc. (LOGC). The firm's subsidiaries include Depixus SAS (EUR), Quench Bio, Inc., Stipe Therapeutics Aps and Twelve Bio Aps.
You don't have any saved screeners yet
